On August 3, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) released its annual report. Highlights from 2022-2023 include:
- Development of procedures for review of nationally procured pharmaceuticals and delivery of implementation advice for certain COVID-19 treatments.
- Reports on evidence and resources for post-COVID condition (also known as long COVID).
- Creation of new reimbursement review pathways including the Non-Sponsored Single Drug Review and Streamlined Drug Class Review and a consultation on time-limited drug reimbursement recommendations.
- Creation of the Post-Market Drug Evaluation Program.
- Release of the 2023 Watch List: Top 10 Precision Medicine Technologies and Issues.
- Start of a learning period and development of draft guidance regarding the use of real-world evidence.
- Report on a potential pan-Canadian formulary.
Related Publications & Articles
-
CDA–AMC (formerly CADTH) announces several pilot projects, including Target Zero initiative
CADTH is now known as Canada’s Drug Agency (CDA-AMC or CDA). Its mandate extends beyond CADTH’s mandate.Read More -
PMPRB releases Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines
On June 26, 2024, the Patented Medicine Prices Review Board (PMPRB) released a Discussion Guide for its Phase 2 Consultations on its New Guidelines.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More